Press coverage about Calithera Biosciences (NASDAQ:CALA) has trended positive on Wednesday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Calithera Biosciences earned a news impact score of 0.28 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.6497904334692 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
CALA has been the subject of several research analyst reports. William Blair initiated coverage on Calithera Biosciences in a research report on Thursday, October 5th. They issued an “outperform” rating for the company. Zacks Investment Research upgraded Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research report on Monday, November 6th. ValuEngine cut Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub cut Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 9th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $15.17.
Calithera Biosciences (NASDAQ CALA) traded down $0.50 during midday trading on Wednesday, reaching $8.05. The company’s stock had a trading volume of 444,100 shares, compared to its average volume of 374,780. The company has a market cap of $299.78, a PE ratio of -8.13 and a beta of 2.87. Calithera Biosciences has a 12-month low of $4.00 and a 12-month high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.02 million. sell-side analysts expect that Calithera Biosciences will post -0.77 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/17/favorable-media-coverage-somewhat-unlikely-to-affect-calithera-biosciences-cala-stock-price.html.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.